EA201501001A1 - VACCINE FOR PREVENTION AND TREATMENT OF ROTAVIRAL INFECTION CONTAINING A HYBRID PROTEIN AS AN ACTIVE AGENT (OPTIONS) - Google Patents

VACCINE FOR PREVENTION AND TREATMENT OF ROTAVIRAL INFECTION CONTAINING A HYBRID PROTEIN AS AN ACTIVE AGENT (OPTIONS)

Info

Publication number
EA201501001A1
EA201501001A1 EA201501001A EA201501001A EA201501001A1 EA 201501001 A1 EA201501001 A1 EA 201501001A1 EA 201501001 A EA201501001 A EA 201501001A EA 201501001 A EA201501001 A EA 201501001A EA 201501001 A1 EA201501001 A1 EA 201501001A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vaccine
hybrid protein
proposed
prevention
proteins
Prior art date
Application number
EA201501001A
Other languages
Russian (ru)
Other versions
EA031404B1 (en
Inventor
Илья Владимирович ДУХОВЛИНОВ
Александр Леонидович КАДЫКОВ
Андрей Семенович СИМБИРЦЕВ
Original Assignee
Общество С Ограниченной Ответственностью "Рд-Биотех" (Ооо "Рд-Биотех")
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Рд-Биотех" (Ооо "Рд-Биотех") filed Critical Общество С Ограниченной Ответственностью "Рд-Биотех" (Ооо "Рд-Биотех")
Publication of EA201501001A1 publication Critical patent/EA201501001A1/en
Publication of EA031404B1 publication Critical patent/EA031404B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Группа изобретений относится к молекулярной биологии, биотехнологии, медицине и предназначена для профилактики и лечения ротавирусной инфекции. Предложена вакцина против ротавирусной инфекции на основе гибридного белка, состоящего из иммуногенных эпитопов белков VP6 и VP8, соединенных гибким мостиком. Также предложена вакцина против ротавирусной инфекции на основе гибридного белка, состоящего из иммуногенных эпитопов белков VP6 и VP8 и адъюванта - фрагментов флагеллина, соединенных гибкими мостиками. Активный компонент вакцины представлен шестью аминокислотными последовательностями (SEQ ID NO :1-SEQ ID NO :6). Активный компонент вакцины получают в клетках прокариот и эукариот с использованием технологии рекомбинантной ДНК и разных методик очистки. Показана иммунологическая поливалентность гибридных белков против ротавируса групп А, В и С. Показано профилактическое и терапевтическое действие предложенных вакцин. Использование данных вакцин позволит обеспечить универсальную защиту человека от ротавирусов.The group of inventions relates to molecular biology, biotechnology, medicine and is intended for the prevention and treatment of rotavirus infection. A vaccine against rotavirus infection based on a hybrid protein consisting of immunogenic epitopes of VP6 and VP8 proteins connected by a flexible bridge is proposed. A vaccine against rotavirus infection based on a hybrid protein consisting of immunogenic epitopes of VP6 and VP8 proteins and an adjuvant — fragments of flagellin, connected by flexible bridges, is also proposed. The active component of the vaccine is represented by six amino acid sequences (SEQ ID NO: 1-SEQ ID NO: 6). The active component of the vaccine is obtained in cells of prokaryotes and eukaryotes using recombinant DNA technology and various purification techniques. The immunological polyvalence of hybrid proteins against rotavirus groups A, B, and C is shown. The preventive and therapeutic effects of the proposed vaccines are shown. The use of these vaccines will provide universal protection for humans against rotaviruses.

EA201501001A 2013-05-15 2014-04-30 Vaccine for the prophylaxis and treatment of rotavirus infection with a fusion protein as active agent (variants) EA031404B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2013122473/15A RU2539913C2 (en) 2013-05-15 2013-05-15 Vaccine for prevention and treatment of rotaviral infection containing hybrid protein as active agent (versions)
PCT/RU2014/000318 WO2014185817A2 (en) 2013-05-15 2014-04-30 Vaccine for the prophylaxis and treatment of rotavirus infection with a fusion protein as active agent (variants)

Publications (2)

Publication Number Publication Date
EA201501001A1 true EA201501001A1 (en) 2016-04-29
EA031404B1 EA031404B1 (en) 2018-12-28

Family

ID=51898956

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201501001A EA031404B1 (en) 2013-05-15 2014-04-30 Vaccine for the prophylaxis and treatment of rotavirus infection with a fusion protein as active agent (variants)

Country Status (3)

Country Link
EA (1) EA031404B1 (en)
RU (1) RU2539913C2 (en)
WO (1) WO2014185817A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109517043B (en) * 2018-11-23 2022-06-14 艾美诚信生物制药有限公司 Purification method of prokaryotic expression recombinant rotavirus antigen P2-VP8
WO2022040334A1 (en) 2020-08-18 2022-02-24 Enviro Metals, LLC Metal refinement

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838497B2 (en) * 2006-12-13 2010-11-23 Susavion Biosciences, Inc. Pro-angiogenic peptides
CN101679498B (en) * 2007-04-05 2013-07-31 西姆拜奥泰克生物技术领域研究开发有限责任公司 Bis-met histones
CA2698413A1 (en) * 2010-04-06 2011-10-06 Denis Archambault Rotavirus vaccine
KR101680903B1 (en) * 2010-12-14 2016-11-30 단국대학교 산학협력단 Transformants expressing epitope of porcine epidemic diarrhea virus and rotavirus and vaccine composition containing the same
CN102643348B (en) * 2012-04-17 2014-07-02 中国医学科学院医学生物学研究所 Recombinant chimeric protein carrying rotavirus antigen epitope and preparation thereof

Also Published As

Publication number Publication date
EA031404B1 (en) 2018-12-28
RU2539913C2 (en) 2015-01-27
RU2013122473A (en) 2014-11-20
WO2014185817A3 (en) 2015-03-12
WO2014185817A2 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
JP2011250797A5 (en)
RU2016146801A (en) VACCINE COMPOSITION AGAINST INFECTION CAUSED BY STREPTOCOCCUS SUIS
IL276210B2 (en) Mers-cov vaccine
JP2016539946A5 (en)
JP2008530245A5 (en)
JP2008529558A5 (en)
HRP20220924T1 (en) Pd-l1 based immunotherapy
RU2015132962A (en) IMMUNOGENIC COMPOSITIONS BASED ON INFLUENZA VIRUS AND THEIR APPLICATION
JP2014534202A5 (en)
EA201290395A1 (en) IMMUNOMODULATING POLYPEPTIDES OBTAINED FROM IL-2 AND THEIR USE FOR THE TREATMENT OF CANCER AND CHRONIC INFECTIONS
AR086078A1 (en) FUSION PROTEINS AND COMBINATION VACCINES
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
JP2014508734A5 (en)
RU2018116601A (en) Immunogenic Fusion Protein
NZ602693A (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
EA201590078A1 (en) VACCINE AGAINST PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE, BASED ON A HYBRID PROTEIN
RU2015101081A (en) STABILIZED GP120
RU2018130813A (en) FMDV VACCINES BASED ON RECOMBINANT Adenovirus VECTOR AND THEIR APPLICATION
ES2898701T3 (en) Truncated rotavirus VP4 protein and application thereof
AR053372A1 (en) IMMUNOLOGICAL PROTEINS OF LAWSONIA INTRACELLULARIS
RU2015119523A (en) A NEW METHOD FOR TREATING SPINAL CORD INJURY USING THE HMGB1 FRAGMENT
RU2015106916A (en) CLOSTRIDIUM DIFFICILE POLYPEPTIDES AS A VACCINE
JP2012102105A5 (en)
EA201690115A1 (en) COMBINED IMMUNOGENIC COMPOSITIONS
RU2015140603A (en) INFLUENZA VIRUS NUCLEOPROTEIN VACCINES

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ